https://www.accessnewswire.com/newsroom/en/bi...ro-1174370
POTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"
According to Ascendiant, the updated report highlights the Company's clinical progress and states that additional clinical data and progress in 2026 could serve as strong catalysts for IGC Pharma's stock.
IGC Pharma's lead program, IGC-AD1, is currently being evaluated in the Phase 2 CALMA clinical trial for agitation associated with Alzheimer's disease. The Company continues to advance CALMA toward its next operational and clinical milestones.
The Ascendiant report, entitled "Reports Q1 2026. We believe more positive clinical data and progress in 2026 to be strong catalysts for stock. Raising P/T to $5.50," may be obtained directly from Ascendiant Capital Markets: Link.
All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC does not endorse, adopt, or guarantee the accuracy, completeness, conclusions, projections, or recommendations contained in any analyst report and undertakes no obligation to update or correct such information.